Gyrodyne , LLC (NASDAQ:GYRO – Get Free Report) saw a significant decrease in short interest in July. As of July 31st, there was short interest totaling 362 shares, a decrease of 48.5% from the July 15th total of 703 shares. Based on an average trading volume of 2,039 shares, the short-interest ratio is currently 0.2 days. Currently, 0.0% of the shares of the company are short sold.
Hedge Funds Weigh In On Gyrodyne
A hedge fund recently bought a new position in Gyrodyne stock. Susquehanna International Group LLP bought a new stake in Gyrodyne , LLC (NASDAQ:GYRO – Free Report) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 14,186 shares of the real estate investment trust’s stock, valued at approximately $142,000. Susquehanna International Group LLP owned about 0.65% of Gyrodyne as of its most recent filing with the Securities & Exchange Commission. 71.36% of the stock is currently owned by hedge funds and other institutional investors.
Gyrodyne Stock Down 0.7%
Shares of GYRO traded down $0.04 during midday trading on Friday, reaching $5.40. 6,442 shares of the stock were exchanged, compared to its average volume of 1,535. Gyrodyne has a twelve month low of $5.31 and a twelve month high of $11.00. The business’s 50-day moving average price is $5.88 and its 200 day moving average price is $7.28.
About Gyrodyne
Gyrodyne Company of America, Inc is a New York–based real estate investment and development firm specializing in medical office buildings and professional facilities. Listed on the NASDAQ under the ticker GYRO, the company’s principal business activity is the ownership, leasing and management of commercial properties tailored to healthcare and life sciences tenants. By focusing on outpatient diagnostic and treatment centers, clinical laboratories and related professional suites, Gyrodyne generates steady rental income and seeks to provide purpose-built environments that meet the specific needs of medical practitioners and research organizations.
The company’s core property portfolio is anchored by an approximately 87-acre campus situated in Stony Brook, Long Island.
Featured Articles
- Five stocks we like better than Gyrodyne
- The Metals Company’s Big Bet Now Comes Down to a License
- OneSpaWorld Keeps Turning Cruise Demand Into Record Earnings
- Meta and Tesla Are Rebounding From Oversold Levels—Now What?
- AMG’s Alternatives Boom Powers Record Growth
Receive News & Ratings for Gyrodyne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyrodyne and related companies with MarketBeat.com's FREE daily email newsletter.
